Skip to Main Content

Bristol-Myers Squibb (BMY), seeking to re-energize its cancer pipeline, is turning to an artificial intelligence startup for help, inking a deal to use the firm’s analytical tools and “real-world” patient data to better target and accelerate clinical trials.

The deal with Concerto HealthAI, a Boston-based firm backed by the $1 billion SymphonyAI fund, is an effort to infuse real-world evidence from medical practices across the U.S. into Bristol’s research. Concerto uses data from CancerLinQ, a national repository of information on cancer patients, to search for patterns that may inform drug development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED